2-(4-bromopent-4-enyloxy)tetrahydro-2H-pyran | 935460-11-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: 2-(4-bromopent-4-enyloxy)tetrahydro-2H-pyran
• 英文别名: 2-(4-bromopent-4-enoxy)oxane
• CAS: 935460-11-0
• 化学式: C₁₀H₁₇BrO₂
• 分子量: 249.148
• InChiKey: NARWPYRALODUDG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-bromopent-4-enyloxy)tetrahydro-2H-pyran 在 甲醇 、 camphor-10-sulfonic acid 作用下， 生成 4-bromopent-4-en-1-ol
  参考文献：
  名称：

  Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: Structure–activity relationship of P2′ substituents

  摘要：

  Herein we describe further evolution of hydroxyethylamine inhibitors of BACE-1 with enhanced permeability characteristics necessary for CNS penetration. Variation at the P2' position of the inhibitor with more polar substituents led to compounds 19 and 32, which retained the potency of more lipophilic analog 1 but with much higher observed passive permeability in MDCK cellular assay. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.06.112
• 作为产物：
  描述：

  2-(4-戊炔氧基)四氢-2H-吡喃 在 9-溴-9-硼杂双环-[3.3.1]壬烷 、 溶剂黄146 作用下， 以 二氯甲烷 为溶剂， 生成 2-(4-bromopent-4-enyloxy)tetrahydro-2H-pyran
  参考文献：
  名称：

  Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: Structure–activity relationship of P2′ substituents

  摘要：

  Herein we describe further evolution of hydroxyethylamine inhibitors of BACE-1 with enhanced permeability characteristics necessary for CNS penetration. Variation at the P2' position of the inhibitor with more polar substituents led to compounds 19 and 32, which retained the potency of more lipophilic analog 1 but with much higher observed passive permeability in MDCK cellular assay. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.06.112

文献信息

• Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors
  申请人：Hom Roy

  公开号：US20070149525A1

  公开（公告）日：2007-06-28

  The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

  本发明涉及新型化合物和治疗与淀粉样变疾病、疾患和症状有关的方法。淀粉样变疾病指与A-beta蛋白异常沉积有关的一系列疾病、疾患和症状。
• WO2007/47306
  申请人：——

  公开号：——

  公开（公告）日：——
• METHODS OF TREATING AMYLOIDOSIS USING ARYL-CYCLOPROPYL DERIVATIVE ASPARTYL PROTEASE INHIBITORS
  申请人：Elan Pharmaceuticals Inc.

  公开号：EP1937638A1

  公开（公告）日：2008-07-02
• [EN] METHODS OF TREATING AMYLOIDOSIS USING ARYL-CYCLOPROPYL DERIVATIVE ASPARTYL PROTEASE INHIBITORS<br/>[FR] METHODES DE TRAITEMENT DE L'AMYLOSE AU MOYEN DE DERIVES ARYL-CYCLOPROPYLE INHIBITEURS D'ASPARTYL-PROTEASES
  申请人：ELAN PHARM INC

  公开号：WO2007047306A1

  公开（公告）日：2007-04-26

  [EN] The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.
  [FR] L'invention concerne de nouveaux composés et de nouvelles méthodes pour traiter des maladies, des troubles et des états associés à l'amylose. Le terme amylose regroupe un ensemble de maladies, troubles et états associés à un dépôt anormal de protéine A bêta.
• Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: Structure–activity relationship of P2′ substituents
  作者：Anh P. Truong、Gary D. Probst、Jose Aquino、Larry Fang、Louis Brogley、Jennifer M. Sealy、Roy K. Hom、John A. Tucker、Varghese John、Jay S. Tung、Michael A. Pleiss、Andrei W. Konradi、Hing L. Sham、Michael S. Dappen、Gergley Tóth、Nanhua Yao、Eric Brecht、Hu Pan、Dean R. Artis、Lany Ruslim、Michael P. Bova、Sukanto Sinha、Ted A. Yednock、Wes Zmolek、Kevin P. Quinn、John-Michael Sauer

  DOI：10.1016/j.bmcl.2010.06.112

  日期：2010.8

  Herein we describe further evolution of hydroxyethylamine inhibitors of BACE-1 with enhanced permeability characteristics necessary for CNS penetration. Variation at the P2' position of the inhibitor with more polar substituents led to compounds 19 and 32, which retained the potency of more lipophilic analog 1 but with much higher observed passive permeability in MDCK cellular assay. (C) 2010 Elsevier Ltd. All rights reserved.